1. Home
  2. TRIN vs NTLA Comparison

TRIN vs NTLA Comparison

Compare TRIN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRIN
  • NTLA
  • Stock Information
  • Founded
  • TRIN 2007
  • NTLA 2014
  • Country
  • TRIN United States
  • NTLA United States
  • Employees
  • TRIN N/A
  • NTLA N/A
  • Industry
  • TRIN Finance/Investors Services
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • TRIN Finance
  • NTLA Health Care
  • Exchange
  • TRIN Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • TRIN 912.3M
  • NTLA 794.5M
  • IPO Year
  • TRIN 2021
  • NTLA 2016
  • Fundamental
  • Price
  • TRIN $14.27
  • NTLA $9.20
  • Analyst Decision
  • TRIN Hold
  • NTLA Buy
  • Analyst Count
  • TRIN 3
  • NTLA 20
  • Target Price
  • TRIN $14.83
  • NTLA $36.60
  • AVG Volume (30 Days)
  • TRIN 667.9K
  • NTLA 6.0M
  • Earning Date
  • TRIN 08-06-2025
  • NTLA 08-07-2025
  • Dividend Yield
  • TRIN 14.30%
  • NTLA N/A
  • EPS Growth
  • TRIN 37.77
  • NTLA N/A
  • EPS
  • TRIN 2.19
  • NTLA N/A
  • Revenue
  • TRIN $240,010,000.00
  • NTLA $45,569,000.00
  • Revenue This Year
  • TRIN $24.11
  • NTLA N/A
  • Revenue Next Year
  • TRIN $4.87
  • NTLA N/A
  • P/E Ratio
  • TRIN $6.52
  • NTLA N/A
  • Revenue Growth
  • TRIN 30.65
  • NTLA N/A
  • 52 Week Low
  • TRIN $12.50
  • NTLA $5.90
  • 52 Week High
  • TRIN $16.82
  • NTLA $28.18
  • Technical
  • Relative Strength Index (RSI)
  • TRIN 40.55
  • NTLA 57.28
  • Support Level
  • TRIN $14.18
  • NTLA $8.00
  • Resistance Level
  • TRIN $14.62
  • NTLA $10.52
  • Average True Range (ATR)
  • TRIN 0.20
  • NTLA 0.67
  • MACD
  • TRIN -0.03
  • NTLA 0.15
  • Stochastic Oscillator
  • TRIN 13.56
  • NTLA 63.35

About TRIN Trinity Capital Inc.

Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: